VIVEVE MEDICAL INC - VIVE STOCK NEWS

Viveve Medical (NASDAQ:VIVE) announced CEO Scott Durbin's participation in the Ladenburg Thalmann Healthcare Conference on July 13-14, 2021. He will deliver a corporate presentation on July 14, 2021, at 1:30 PM ET, which will be webcast live on the company's website. Viveve is focused on women's intimate health and has developed the Viveve® System, which is FDA-cleared for various uses. The company is advancing its clinical program for Stress Urinary Incontinence (SUI) and has recently updated its trial protocol.

Viveve Medical (NASDAQ: VIVE) announced the issuance of U.S. Patent No. 10,980,596 for its dual-energy technology device, further strengthening its intellectual property portfolio. CEO Scott Durbin expressed optimism about advancing global clinical development, supported by recent patent expansions in key markets. The Viveve System, focused on women's intimate health, utilizes patented technology for neocollagenesis. Ongoing clinical trials for stress urinary incontinence (SUI) have seen FDA-approved protocol changes intended to enhance the study's efficacy and size, with positive results potentially leading to new U.S. indications.

Viveve Medical, Inc. (NASDAQ: VIVE) has adjourned its 2021 Annual Meeting of Stockholders due to a lack of quorum, now rescheduled for June 23, 2021, at 12:00 PM ET. The meeting will be virtual, and stockholders are encouraged to vote using various methods including online, by phone, by mail, or during the meeting. Viveve focuses on women's intimate health with its patented Viveve® System approved by the FDA for certain uses. The company is advancing its clinical program for Stress Urinary Incontinence (SUI) with FDA-approved study protocol changes aimed to enhance the trial's effectiveness.

Viveve Medical reports Q1 2021 revenue of $1.5 million, up from $1.3 million in Q1 2020, driven by the sale of 2,450 consumable treatment tips and 8 Viveve Systems. The company has initiated the pivotal PURSUIT clinical trial for stress urinary incontinence (SUI), with patient enrollment accelerating. Gross profit improved to 26% of revenue, while operating expenses decreased to $5.5 million. The net loss narrowed to $6.9 million or $0.80 per share. Cash and equivalents rose significantly to $28.4 million as of March 31, 2021.

Viveve Medical, Inc. (NASDAQ:VIVE) has adjourned its 2021 Annual Meeting of Stockholders due to insufficient quorum, rescheduling it for June 2, 2021, at 12:00 PM Eastern Time. Stockholders are encouraged to cast their votes through various methods, including online and telephone, before the meeting. Viveve specializes in women’s intimate health, utilizing its Viveve System for FDA-cleared procedures. Recent FDA-approved protocol changes to the ongoing PURSUIT trial aim to enhance study efficacy, reflecting ongoing commitment to clinical advancement and shareholder engagement.

Viveve Medical, Inc. (NASDAQ:VIVE) will report its Q1 2021 financial results and corporate updates after market close on May 13, 2021. A conference call will provide insights into the company's performance, with access via phone or webcast. Viveve, focused on women's intimate health, is advancing the pivotal PURSUIT trial for stress urinary incontinence (SUI) in women. Recent FDA protocol changes aim to enhance study efficacy, including increased trial size and stricter patient selection, potentially supporting a new SUI indication in the U.S.

Viveve Medical (NASDAQ: VIVE) announced the issuance of Taiwan Patent No. 1720358 for its dual-energy technology device, enhancing its intellectual property portfolio in a key Asian market. The CEO highlighted Taiwan's importance in regional women's health trends. The Viveve System is used for surgical procedures in Taiwan, with Dynamic Medical Technologies as the exclusive distributor. This patent follows recent patents in South Korea and the U.S. regarding stress urinary incontinence. The company continues to advance its clinical development and commercialization strategies.

Viveve Medical, Inc. (NASDAQ:VIVE) reported its 2020 financial results, showing total revenue of approximately $5.5 million, a decline from 2019 due to the pandemic's impact on healthcare operations. The company is advancing its pivotal U.S. PURSUIT trial for stress urinary incontinence (SUI), potentially addressing a $3 billion market. Key highlights include a reduced net loss of $26.1 million and improved operational efficiency following strategic realignment. The company successfully completed a $27.6 million financing to support ongoing operations and the SUI trial.

Viveve Medical, Inc. (NASDAQ:VIVE), a leader in women's intimate health technology, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. CEO Scott Durbin will deliver a virtual presentation starting at 7:00 AM ET on March 9, available on the investor section of their website. Viveve is advancing solutions for women's health, focusing on stress urinary incontinence and has received FDA approvals for its clinical trials. The company's innovative Viveve® System aims to improve women's well-being through effective medical technology.